The MRI-Adapted Prostate Cancer Risk Tool (MAPCaRT)
The MRI-Adapted Prostate Cancer Risk Tool (MAPCaRT) is a pre-radical prostatectomy patient stratification tool that can aid to predict prostate cancer recurrence and assist in clinical decisions using accessible clinicopathologic data. This tool is meant to be used for men who underwent MRI-targeted and/or systematic prostate biopsy, and was validated in a multi-institutional study.1
MAPCaRT is a modified version of the CAPRA tool2. It was developed to adapt to the advent of MRI-targeted prostate biopsy, by replacing the clinical stage and the percentage of biopsy cores involved by prostate cancer with a robust, contemporary prognostic biomarker: the presence or absence of cribriform pattern 4 carcinoma (CC) and/or intraductal carcinoma (IDC) of the prostate.
The MAPCaRT calculator provides a risk score from 0 to 10 which allows classification of patients into the low (scores 0-2), intermediate (scores 3-5) or high (scores 6-10) risk group, with associated 5-year recurrence free survival.
Calculator for MRI-Targeted Biopsy*
Check an item for each parameter.
BCR, biochemical recurrence; CC, cribriform pattern 4 carcinoma; IDC, intraductal carcinoma; PSA, prostate-specific antigen.
*with or without systematic biopsy.
Calculator for Systematic Biopsy
Check an item for each parameter.
BCR, biochemical recurrence; CC, cribriform pattern 4 carcinoma; IDC, intraductal carcinoma; PSA, prostate-specific antigen.
References:
[1] Nguyen NNJ, Liu K, Lajkosz K, Bernardino R, Yin LB, Hollemans E, Kroon LJ, Fleshner N, van Leenders GJLH, Iczkowski KA, van der Kwast TH, Downes MR. MRI-adapted prostate cancer risk tool incorporating cribriform and intraductal carcinoma [Manuscript submitted for publication].